Mark McKenna - Feb 1, 2024 Form 4 Insider Report for Spyre Therapeutics, Inc. (SYRE)

Role
Director
Signature
/s/ Heidy King-Jones, as Attorney-in-Fact
Stock symbol
SYRE
Transactions as of
Feb 1, 2024
Transactions value $
$0
Form type
4
Date filed
2/5/2024, 05:29 PM
Previous filing
Aug 21, 2023
Next filing
Feb 8, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SYRE Stock Option (Right to Buy) Award $0 +40K $0.00 40K Feb 1, 2024 Common Stock 40K $25.86 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option represents a right to purchase 40,000 shares of the Issuer's common stock, which will vest and become exercisable in 36 equal monthly installments beginning on February 1, 2024 until such time as the option is 100% vested, subject to the Reporting Person's continuous service with the Issuer at each vesting date.